Content about Diabetes

BEERSE, Belgium — Johnson & Johnson subsidiary Janssen has launched an interactive educational website about diabetes for European healthcare professionals.

Dubbed the Janssen Diabetes Forum, the website is designed to educate users about the latest developments in the management of Type 2 diabetes. The website was launched Tuesday in Beerse, Belgium.

BURNSVILLE, Minn. — A new product from Apothecary Products that has been featured on "The Dr. Oz Show" and "The Today Show" is hoping to remove the guesswork of proper food portions when cooking a meal at home.

SEATTLE — Bartell Drugs will play a prominent role at a diabetes expo in Seattle this weekend, the retail pharmacy chain said Wednesday.

BIRMINGHAM, Ala. — Novo Nordisk has launched a diabetes awareness sweepstakes in which the winners get a free trip to the 2013 IndyCar finale, the Danish drug maker said Friday.

The company announced that it had hired IZOD IndyCar Series Charlie Kimball as spokesman for its Race with Insulin contest. Kimball, the first licensed driver with diabetes to race at the highest level of the series, was diagnosed with the disease during a routine doctor visit in 2007 while racing in Europe and is a user of Novo Nordisk's NovoLog (insulin aspart [rDNA origin]).

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Johnson & Johnson for treating Type 2 diabetes, the agency said.

The FDA announced the approval of J&J subsidiary Janssen Pharmaceuticals' Invokana (canagliflozin) tablets, designed for use with diet and exercise to improve blood-sugar control in adults with the disease.

ATLANTA — The percentage of people who are at risk of developing Type 2 diabetes and aware of it has risen slightly over the past few years, but remains low, according to a report by the Centers for Disease Control and Prevention.

RIDGEFIELD, Conn. — Boehringer Ingelheim and Eli Lilly are seeking regulatory approval for an experimental drug to treat Type 2 diabetes, the companies said Monday.

BI and Lilly announced the submission of a regulatory application to the Food and Drug Administration for empagliflozin. The drug belongs to a new drug class known as SGLT2 inhibitors, which work by removing excess glucose through the urine by blocking its reabsorption in the kidneys. The companies are testing the drug in a late-stage clinical trial for which they plan to enroll 14,500 patients.

PITTSBURGH — Mylan has settled a patent-infringement lawsuit filed by Shionogi over its generic version of a drug for diabetes, Mylan said.

The generic drug maker said that under the agreement, it can launch a generic version of Shionogi's Fortamet (metformin hydrochloride) extended-release tablets in the 500-mg and 1,000-mg strengths on Aug. 1.

Metformin hydrochloride extended-release tablets in those two strengths had sales of about $125 million during the 12-month period that ended in September, according to IMS Health.

Sales of glucose meters were slightly up over the holidays, reaching $67.7 million for the 12 weeks ended Dec. 30 across U.S. multi-outlets, according to SymphonyIRI Group data.

With a new diabetes diagnosis being made once every 21 seconds, coupled with the coming expansion of Medicaid requirements across at least some states, there will be a significant consumer demand for blood-glucose meters and the test strips that supply them for some time to come.

ALEXANDRIA, Va. — The cost of diabetes has increased by more than $70 billion over the past five years, according to new research from the American Diabetes Association.

The ADA announced the release of a report estimating that the total costs of diagnosed diabetes had risen 41%, from 2007's $174 billion to $245 billion in 2012. The report, Economic Costs of Diabetes in the U.S. in 2012, was commissioned by the ADA and addresses increased financial burden, health resources used and lost productivity associated with the disease.

The YMCA is offering a demonstration project to show that its YMCA Diabetes Prevention Program — part of the Centers for Disease Control and Prevention's broader National Diabetes Prevention Program — can lower the incidence of Type 2 diabetes and reduce medical costs incurred by Medicare.